Elixirgen Therapeutics is strategically developing a pipeline focused on rare diseases linked to telomere biology disorders (TBD) and Duchenne Muscular Dystrophy (DMD). Founded in 2017, the company is leveraging its proprietary ZSCAN4 technology to target aging-related diseases and mRNA-based therapies. The most advanced candidate, EXG-7001, aims to deliver a full-length dystrophin protein for DMD patients, addressing a significant unmet need in the current treatment landscape.
Elixirgen’s recent partnership with Japan’s Nippon Shinyaku underscores its commitment to advancing this therapy, with funding for development costs and potential milestone payments. The innovative approach of EXG-7001, utilizing a localized mRNA delivery system, aims to circumvent common issues associated with systemic gene therapies, such as liver accumulation. This could enhance the safety and efficacy of treatments for DMD and other diseases involving large genes.
Additionally, Elixirgen is progressing its ZSCAN4-based therapy for TBDs, with promising early clinical results indicating durable telomere extension and safety. As the company continues to explore various applications of its technology, it positions itself at the forefront of addressing both rare genetic disorders and broader aging-related conditions, potentially transforming treatment paradigms in these areas.
Use the database as your supply chain compass →
